MedTrace Logo

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

NCT05160480 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2026-03-10

No results posted yet for this study

Summary

The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).

Conditions

Interventions

DIAGNOSTIC_TEST

Total-body PET imaging

Total-body PET imaging at different timepoints

Sponsors & Collaborators

  • Lantheus Medical Imaging

    collaborator INDUSTRY

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Lorenzo Nardo, MD · University of California, Davis

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-07
Primary Completion
2026-09-01
Completion
2026-09-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05160480 on ClinicalTrials.gov